Caladrius Biosciences (NASDAQ: CLBS) and American Renal Associates (NYSE:ARA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.
Risk and Volatility
Caladrius Biosciences has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, American Renal Associates has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500.
This table compares Caladrius Biosciences and American Renal Associates’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Caladrius Biosciences||$35.28 million||1.25||$22.97 million||($1.78)||-2.60|
|American Renal Associates||$745.11 million||0.69||$4.85 million||$0.61||26.90|
Caladrius Biosciences has higher earnings, but lower revenue than American Renal Associates. Caladrius Biosciences is trading at a lower price-to-earnings ratio than American Renal Associates, indicating that it is currently the more affordable of the two stocks.
This table compares Caladrius Biosciences and American Renal Associates’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|American Renal Associates||-1.00%||14.51%||2.06%|
This is a breakdown of current ratings for Caladrius Biosciences and American Renal Associates, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|American Renal Associates||0||1||2||0||2.67|
Caladrius Biosciences presently has a consensus target price of $9.50, indicating a potential upside of 105.18%. American Renal Associates has a consensus target price of $23.50, indicating a potential upside of 43.21%. Given Caladrius Biosciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Caladrius Biosciences is more favorable than American Renal Associates.
Insider & Institutional Ownership
5.7% of Caladrius Biosciences shares are held by institutional investors. Comparatively, 91.6% of American Renal Associates shares are held by institutional investors. 13.1% of Caladrius Biosciences shares are held by insiders. Comparatively, 9.6% of American Renal Associates shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
American Renal Associates beats Caladrius Biosciences on 7 of the 13 factors compared between the two stocks.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2017, it owned and operated 228 dialysis clinics in partnership with 401 nephrologist partners treating approximately 15,600 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.